These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8102130)

  • 21. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas.
    Satoh K; Sasano H; Shimosegawa T; Koizumi M; Yamazaki T; Mochizuki F; Kobayashi N; Okano T; Toyota T; Sawai T
    Cancer; 1993 Jul; 72(1):51-6. PubMed ID: 8099533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study.
    Suwanagool P; Parichatikanond P; Maeda S
    Asian Pac J Allergy Immunol; 1993 Dec; 11(2):119-22. PubMed ID: 7915904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer.
    Gardiner RA; Samaratunga ML; Walsh MD; Seymour GJ; Lavin MF
    Urol Res; 1992; 20(2):117-20. PubMed ID: 1348155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
    Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry.
    Dawkins HJ; Robbins PD; Sarna M; Carrello S; Harvey JM; Sterrett GF
    Pathology; 1993 Apr; 25(2):124-32. PubMed ID: 8103591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast.
    Walker RA; Dearing SJ
    Eur J Cancer; 1992; 28(2-3):641-4. PubMed ID: 1317202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.
    Arnaout AH; Dawson PM; Soomro S; Taylor P; Theodorou NA; Feldmann M; Fendly BM; Shepard HM; Shousha S
    J Clin Pathol; 1992 Aug; 45(8):726-7. PubMed ID: 1357006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
    Looi LM; Cheah PL
    Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of c-erbB3 protein in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty MK
    Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of immunohistochemically detected c-erbB-2 protein expression in stage III breast cancer, with reference to nuclear deformity, DNA content and prognosis.
    Tamura G; Maesawa C; Mikawa S; Satodate R
    Jpn J Clin Oncol; 1991 Aug; 21(4):264-7. PubMed ID: 1682519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
    Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
    J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening.
    Cowan WK; Angus B; Henry J; Corbett IP; Reid WA; Horne CH
    Br J Cancer; 1991 Oct; 64(4):780-4. PubMed ID: 1680369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; de Vries J; Wesseling J; de Bock GH
    Ann Surg Oncol; 2007 Jul; 14(7):2097-104. PubMed ID: 17453296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
    Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
    Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
    Looi LM; Cheah PL; Yap SF
    Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis.
    Schmitt FC; Figueiredo P; Lacerda M
    Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-erbB-2 protein and neuroendocrine expression in breast carcinomas.
    Nesland JM; Ottestad L; Heikilla R; Holm R; Tveit K; Børresen AL
    Anticancer Res; 1991; 11(1):161-7. PubMed ID: 1673329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast.
    De Potter CR; Foschini MP; Schelfhout AM; Schroeter CA; Eusebi V
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(5):375-80. PubMed ID: 8100656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.